Avectas Raises $10 Million in Equity Finance

Investment Will Be Used To Advance the Development of Solupore®, its non-viral cell engineering technology

News provided by

Avectas

09 Apr, 2019, 14:21 GMT

DUBLIN, April 9, 2019 /PRNewswire/ -- Cell engineering technology business Avectas has completed a US$10 million equity financing with a group of experienced biotechnology investors. The investment round was led by leading pharmaceutical sector investor Seamus Mulligan.  Avectas collaborates with leading cell and gene therapy businesses and academic institutions to address their cell engineering challenges using its patented Solupore® technology. 

Continue Reading
This image opens in the lightbox
Avectas cofounder and chief Executive Dr Michael Maguire, with cofounder Dr Shirley O'Dea, Chief Scientific Officer and business development Director Dr Gillian Hendy.

"The Avectas team is delighted to receive this significant endorsement from a highly experienced group of investors," said Dr. Michael Maguire, co-founder and CEO of Avectas. "This funding, which builds on our recent Horizon 2020 award, provides us with the financial resources to accelerate the development, scale-up and commercialisation of Solupore®."

Cell and gene therapies offer the potential to transform the treatment of diseases, including cancer, for millions of patients worldwide. However new engineering technologies are required to enable these cutting-edge therapies to achieve their potential. Avectas is developing a patented, non-viral, cell engineering technology which efficiently engineers therapeutic cells, at scale, while maintaining optimal cell functionality.

About Avectas

Founded in 2012 as a spin-out from Maynooth University in Ireland by Dr. Michael Maguire and Dr. Shirley O'Dea, Avectas has 24 employees including 13 with doctorate degrees.      

Contact: Ray Gordon, Gordon MRM, ray@gordonmrm.ie, +353872417373 

Photo - https://mma.prnewswire.com/media/858917/Avectas_Team.jpg